Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law" represents the first comprehensive update in 23 years, with over 90% of its provisions modified, focusing on encouraging new drug research and innovation, enhancing market exclusivity, data protection, and segmented production [3][4][5]. Encouragement of New Drug Research and Innovation - A significant focus of the revised regulations is the encouragement of new drug research and innovation, including the establishment of accelerated drug registration processes and market exclusivity for pediatric and rare disease medications [4][5]. - Article 15 of the revised regulations outlines four accelerated approval procedures for eligible drug applications, enhancing the legal basis for administrative efficiency in drug review processes [5][6]. - Market exclusivity provisions include up to 2 years for pediatric drugs and up to 7 years for rare disease drugs, addressing the gap in available treatments and the challenges in clinical trials for these categories [5][6]. Data Protection and Patent Linkage - The revised regulations include provisions for data protection for drugs with new chemical entities, allowing for the protection of undisclosed clinical trial data for various scenarios, including innovative and modified new drugs [7]. - Although "patent term compensation" and "patent linkage" were not included in the revised regulations, existing laws and mechanisms already address these aspects [8]. Benefits for Innovative Pharmaceutical Companies - The comprehensive upgrade of the regulations is expected to provide substantial benefits for innovative pharmaceutical companies, particularly those focused on pediatric and rare disease drugs, as well as first-in-class (FIC) drugs [11]. - The regulations are anticipated to attract capital towards high-efficiency, high-value research-oriented companies, acting as a catalyst for the recovery of the capital market [11]. - Companies are encouraged to focus on unmet clinical needs, particularly in rare diseases and oncology, while also enhancing early commercialization strategies and lifecycle management capabilities [11].

Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law" encourages new drug research and innovation, strengthens market exclusivity, data protection, and segmented production, which are key concerns for companies and the industry [1][2]. Encouragement of New Drug Research and Innovation - A major focus of the revised regulations is to encourage new drug research and innovation, including the establishment of accelerated drug registration procedures, market exclusivity for pediatric and rare disease drugs, and data protection for drugs with new chemical entities [1][2]. - Article 15 of the revised regulations mentions that eligible drug registration applications can adopt breakthrough therapy procedures, conditional approval procedures, priority review and approval procedures, and special approval procedures to accelerate drug market entry [2]. Market Exclusivity and Data Protection - Article 21 states that eligible pediatric drugs can receive a market exclusivity period of up to 2 years, while rare disease drugs can receive up to 7 years [2][3]. - Article 22 specifies that data protection for drugs with new chemical entities can last up to 6 years from the date of drug registration, covering various scenarios including innovative drugs and improved new drugs that have not been marketed domestically [3]. Impact on Drug Production and Industry Guidance - The revised regulations provide top-level, principle-based guidance for industry promotion, allowing drug marketing authorization holders to delegate segmented production to qualified manufacturers [5]. - Article 36 allows for the sale of drugs that meet release requirements after obtaining drug approval documents, which can reduce waste and environmental burdens during the commercialization phase [5]. Financing and Investment Opportunities - The systematic upgrade of the regulations may create substantial benefits for drug company financing by clarifying the lifecycle responsibilities of drug marketing authorization holders and optimizing the separation of holding and production mechanisms [6]. - The regulations are expected to attract capital towards high-efficiency, high-value research-oriented drug companies, with a particular focus on pediatric drugs, rare diseases, and first-in-class (FIC) innovative drugs [6].